Literature DB >> 12384370

In vitro activity of caspofungin against Candida albicans biofilms.

Stefano P Bachmann1, Kacy VandeWalle, Gordon Ramage, Thomas F Patterson, Brian L Wickes, John R Graybill, José L López-Ribot.   

Abstract

Most manifestations of candidiasis are associated with biofilm formation on biological or inanimate surfaces. Candida albicans biofilms are recalcitrant to treatment with conventional antifungal therapies. Here we report on the activity of caspofungin, a new semisynthetic echinocandin, against C. albicans biofilms. Caspofungin displayed potent in vitro activity against sessile C. albicans cells within biofilms, with MICs at which 50% of the sessile cells were inhibited well within the drug's therapeutic range. Scanning electron microscopy and confocal scanning laser microscopy were used to visualize the effects of caspofungin on preformed C. albicans biofilms, and the results indicated that caspofungin affected the cellular morphology and the metabolic status of cells within the biofilms. The coating of biomaterials with caspofungin had an inhibitory effect on subsequent biofilm development by C. albicans. Together these findings indicate that caspofungin displays potent activity against C. albicans biofilms in vitro and merits further investigation for the treatment of biofilm-associated infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384370      PMCID: PMC128731          DOI: 10.1128/AAC.46.11.3591-3596.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections.

Authors:  I Raad; H Hanna
Journal:  Support Care Cancer       Date:  1999-11       Impact factor: 3.603

Review 2.  Molecular organization of the cell wall of Candida albicans.

Authors:  F M Klis; P de Groot; K Hellingwerf
Journal:  Med Mycol       Date:  2001       Impact factor: 4.076

Review 3.  Biofilm formation: a clinically relevant microbiological process.

Authors:  R M Donlan
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

4.  Effect of highly active antiretroviral therapy on frequency of oral warts.

Authors:  D Greenspan; A J Canchola; L A MacPhail; B Cheikh; J S Greenspan
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

5.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 6.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

7.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Authors:  C M Douglas; J A D'Ippolito; G J Shei; M Meinz; J Onishi; J A Marrinan; W Li; G K Abruzzo; A Flattery; K Bartizal; A Mitchell; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Authors:  Stefano P Bachmann; Thomas F Patterson; José L López-Ribot
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

10.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

View more
  95 in total

1.  E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis.

Authors:  Nao-Aki Watanabe; Mamiko Miyazaki; Takaaki Horii; Koji Sagane; Kappei Tsukahara; Katsura Hata
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.

Authors:  Priya Uppuluri; Anand Srinivasan; Anand Ramasubramanian; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 3.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

4.  Aspergillus fumigatus Afssn3-Afssn8 Pair Reverse Regulates Azole Resistance by Conferring Extracellular Polysaccharide, Sphingolipid Pathway Intermediates, and Efflux Pumps to Biofilm.

Authors:  Nanbiao Long; Liping Zeng; Guowei Zhong; Shanlei Qiao; Lei Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Failure of new antifungals to control Candida thrombophlebitis.

Authors:  Mathieu Gazon; Marc O Robert; Serge Duperret; Patricia Branche; Jean P Viale
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

Review 6.  Candida biofilms: an update.

Authors:  Gordon Ramage; Stephen P Saville; Derek P Thomas; José L López-Ribot
Journal:  Eukaryot Cell       Date:  2005-04

7.  Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.

Authors:  Aspasia Katragkou; Athanasios Chatzimoschou; Maria Simitsopoulou; Maria Dalakiouridou; Eudoxia Diza-Mataftsi; Chaido Tsantali; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

8.  In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms.

Authors:  Semanti Sarkar; Priya Uppuluri; Christopher G Pierce; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

9.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Penetration of Candida biofilms by antifungal agents.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.